The overall survival advantage held regardless of PD-L1 status in patients receiving the first-line combination of cadonilimab and standard chemotherapy.
When it comes to the link, a new report from WHO revealed limited or inadequate evidence to suggest consuming less alcohol or stopping altogether reduced the risk for most cancers.